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Sarcoma of the breast is a rare condition. The biological differences from other primary breast tumours
necessitate a corresponding difference in approach to diagnostic and management strategies. The rarity
of the condition has made clinicopathological study difﬁcult, with most series limited to less than 50
patients. We review the current literature on the diagnosis and management of breast sarcoma, and
highlight areas of likely future development.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Breast sarcoma
Sarcoma of the breast is a rare condition. The biological differ-
ences from other primary breast tumours necessitate a corre-
sponding difference in approach to diagnostic and management
strategies.
Primary breast sarcoma can be subdivided into three distinct
subgroups: malignant phyllodes tumours, sarcomas arising in the
post-irradiation breast and primary breast sarcomas.
The majority of phyllodes and primary sarcomas will present as
a palpable mass within the breast tissue. All breast masses should
undergo triple assessment by way of clinical examination, radio-
logical imaging (mammography/sonography) and histological (core
biopsy) or cytological (ﬁne needle aspiration, FNA) analysis.
However, some of these modalities have signiﬁcant drawbacks in
the setting of sarcomatoid malignancies when compared to breast
carcinoma which demand an alteration in diagnostic approach.1.1. Histological/cytological diagnosis
1.1.1. Malignant phyllodes tumours
Phyllodes tumour (PT) is a biphasic stromal malignancy which
contains both epithelial and spindle-cell stromal elements.1 Clini-
cally it can be difﬁcult to distinguish from ﬁbroadenoma. There are
similar histological challenges, largely due to tumour heteroge-
neity. Histopathologically, these lesions consist of epithelially lined
cysts with a hypercellular stroma. The diagnosis of PT is dependentx: þ44 20 7352 2785.
ncavel).
ciates Ltd. Published by Elsevier Ltupon this histopathological appearance and, therefore, pre-
operative diagnosis with by FNA is difﬁcult.
Three subtypes of PT are recognised – benign, borderline and
malignant – on the basis of histological characteristics of the
stromal elements. Whilst benign PTs are similar in behavior to
ﬁbroadenomas, in that they rarely recur or metastasise, malignant
phyllodes tumours (MPT) carry a signiﬁcant risk of recurrence and
metastasis. Pre-operative diagnosis is, therefore, critical.
Studies have shown the diagnostic rates for PT on ﬁne needle
aspiration to be comparatively poor, at around 23%.2–4 The accuracy
of the test improves when these ﬁndings are considered in
combination with imaging ﬁndings. Rates of positive diagnosis
increase with core biopsy.5 Bode et al retrospectively analysed the
core biopsies of 64 lesions, and found sensitivity and speciﬁcity of
83% and 92%, with a negative predictive value of 96%.6 Hoeber et al
suggest a sensitivity and speciﬁcity of >98% in STS.36 The majority
of phyllodes tumours can, therefore, be diagnosed pre-operatively
using a combination of imaging and pre-operative core biopsy. We
would suggest core biopsy, in combination with imaging, as the
most appropriate method of pre-operative assessment. Diagnostic
excision biopsy should rarely be indicated.
1.1.2. Primary breast sarcoma
As in PT, primary breast sarcoma is easily confused with
ﬁbroadenoma on cytological analysis. However, unlike the
heterogeneous phyllodes group, the consequences of being falsely
reassured by negative cytology are potentially more serious. One
study of 28 cases found that FNAwas reported as benign in all cases
of non-epithelial breast malignancy in which it was used, while
core biopsy again produced a signiﬁcant improvement in diagnosis
rates.4 Although Chhieng et al analysed the FNA ﬁndings ind. All rights reserved.
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indicated that a positive diagnosis was reached in 83%7 the
necessity for ﬁrm pre-operative diagnosis is paramount, and the
improved yield from core biopsy makes this the investigation of
choice.
1.1.3. Radiation-induced sarcoma
The presentation of post-irradiation sarcoma is normally
slightly different to the primary mesenchymal malignancies.
Clearly, the presence of a palpable mass in a breast previously
irradiated will raise the possibility of recurrent tumour. The rate of
recurrence following breast-conserving therapy (BCT) for epithelial
malignancies of the breast is in the region of 3%, whereas the rate of
sarcoma in the previously irradiated breast is 0.02%.8–11 The com-
monest post-irradiation sarcoma is angiosarcoma (more than 50%,
as opposed to 20% in the radiation-naı¨ve breast8,12,13), and normally
presents as raised, red–blue papules. The diagnosis has become
slightly more complex with the move towards diagnosis of atypical
vascular proliferations, which has gained more widespread accep-
tance in recent times. This condition is easily confused with low-
grade angiosarcoma.14 Diagnosis of sarcoma in the post-BCT patient
is, therefore, similar to other mesenchymal tumours, with core and
punch biopsy preferable to FNA.1.2. Diagnostic imaging
1.2.1. Malignant phyllodes tumour
Mammography in MPT is non-speciﬁc. It appears as a well-
deﬁned, smooth lesion, occasionally with a peri-lesional halo,
representing compression of surrounding normal breast tissue.3,15
Although up to 75% of mammograms show an abnormality, no
speciﬁc criteria exist which allow differentiation of benign from
malignant lesions.
Ultrasonography shows an abnormality more often than plain
mammography, most frequently a hypoechoic, heterogeneous, oval
or lobulated mass.3,6,15 Again no features have yet been proven to
be able to reliably distinguish benign from malignant lesions.
Magnetic resonance imaging seems to be more helpful at accurate
delineation of extent of disease but has similar disadvantages to
other modalities.18Fig. 1. Mammographic appearance of a small, low-g1.2.2. Primary breast sarcoma
Mammographic ﬁndings in sarcoma are also non-speciﬁc.
Depending on type, it may appear as a nonspiculated dense mass
with indistinct borders to areas of asymmetry or even no
mammographic abnormality at all.16–18 In one small series of
angiosarcoma, 33% of tumours fell into the last two categories.17
Interestingly, all of the tumours were visible on ultrasonography.
However, the sonographic ﬁndings were more heterogeneous –
whilst the majority were hyperechoic (13/24), others showed
mixed hyper- or hypo-echogenicity.
Unlike MPT, magnetic resonance in primary breast sarcoma can
indicate malignancy. The tumours are lobulated and display rapid
enhancement and so-called ‘washout’ characteristics, all of which
may be helpful in suggesting the diagnosis of malignancy.17
1.3. Management
1.3.1. Surgery
Unlike the diagnostic differences between MPT and primary
sarcoma, the management of these conditions can be considered
together.5,21 The mainstay of treatment of sarcoma of the breast,
as with sarcomas at other sites, is surgical.
To date, only two factors have been shown to deﬁnitely affect
outcome following primary surgery for sarcoma – the size of the
primary tumour and the excision margin.19–22 Various other factors
have been suggested, such as tumour grade or contour, but these
have not consistently shown a signiﬁcant impact.12,15,20,23
Analysis of survival rates of patients offeredmastectomy or wide
local excision have not shown any signiﬁcant advantage to more
radical surgery.24 However, with large tumours, a mastectomy may
be necessary to obtain clearance. Angiosarcoma, which is the
commonest histological subtype in radiation induced sarcomas, has
a particularly inﬁltrative margin and obtaining histologically clear
margins by breast conservation is more difﬁcult than in other
histological subtypes. Since sarcoma is a rare disease in itself, there
are no consensus guidelines for margins within the breast. Most
authors agree that 1 cm margins are sufﬁcient for small, localized
sarcomas, and this approach is compatible with breast-conserving
surgery (Fig. 1). However, angiosarcoma, with its inﬁltrative cuta-
neous margins may require larger margins, up to 3 cm, hence the
need for associated reconstructive procedures (Fig. 2).25,26 In therade sarcoma, suitable for wide local excision.
Fig. 2. (a) shows angiosarcoma of the left breast; (b) is an intraoperative picture showing the wide margins necessary for this excision; (c) at the end of the operation, with
a transverse rectus abdominis (TRAM) ﬂap used for reconstruction.
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as further adjuvant radiotherapy cannot be administered.
The relationship between tumour size and outcome is less
ambiguous. Multiple studies have shown that tumours larger than
5 cm carry a worse prognosis than smaller lesions.5,20 Tumour
grade, despite being associatedwith poorer prognosis inmost other
primary malignancies, at best shows a trend towards worse prog-
nosis in higher-grade sarcomas but in most studies there is no
signiﬁcant impact. However, given the strong relationship between
grade and outcome in sarcoma generally the failure to demonstrate
a clear association between grade and outcome is probably
a consequence of the small number of patients in published breast
sarcoma series.
Disease-free survival rates range from 44% to 74% at 5 years
following adequate surgery, with signiﬁcantly poorer rates for
patients treated by enucleation alone (one study of MPT suggested
an 85% recurrence rate for tumours treated in this fashion27).
Overall survival rates were higher than disease-free survival, at
between 61% and 91%.11,12,15,28,29
Unlike primary epithelial-type breast malignancies, elective
lymph node dissection is not to be recommended in sarcoma. Since
sarcoma predominantly exhibits haematogenous patterns of
spread, the rate of nodal metastasis is low, quoted in most studies
as less than 5% (although as high as 10% in MPT).20,28,30,31 Elective
lymphadenectomy exposes the patient to considerable additional
morbidity with no discernable beneﬁt in terms of either disease-
free or overall survival.4,11,31 Lymph node metastases are seen most
commonly in patients with signiﬁcant, disseminated, end-stage
disease and in this context it is doubtful whether lymphadenec-
tomy is of any beneﬁt.32 It is interesting to note that lymph nodes
may be palpable in up to 25% of cases, but tend to be reactive rather
than involved in the malignant process.16 In summary, operations
on lymph node basins should only be undertaken in the presence of
histologically proven recurrence in a nodal basin which is either
isolated or where the aim of surgery is local disease control and
symptom relief. Under these circumstances, radical block dissection
may be indicated.1.3.2. Adjuvant therapy
Radiotherapy and chemotherapy both have a role to play in the
management of breast sarcoma. As outlined above, the primary
modality must always be surgical, but survival advantages have
been shown, particularly with radiotherapy.
One of the largest series of primary sarcoma, 78 patients from
the University of Toronto, found cause-speciﬁc survival for post-
operative patients improved from 50% to 91% with a course of
>48 gy.32 They concluded that this would be an appropriate dose,
with at least 60 gy to the tumour bed. Most series show, at the very
least, a trend towards improved survival, and as experience has
progressed, most now recommend adjuvant radiotherapy in the
radiation-naı¨ve breast.5,25,33
The role of chemotherapy is less clear. The MD Anderson series
of 60 patients showed that adjuvant chemo- or radiotherapy was
associated with an improved disease-free survival, but on the
whole response rates to systemic therapy are disappointing.5,31 In
vivomodels indicated tumour sensitivity to doxorubicin, vincristine
and cyclophosphamide but these ﬁndings have not been repeated
in general. Complete and partial responses are seen, with rates
approaching 50% for some combination therapies,4,11,15,28 but
although trends towards improved survival have been shown,
signiﬁcant improvements are not seen.
1.4. Future directions
Most studies of breast sarcoma are relatively small, an unfor-
tunate necessity given the rarity of the condition. However, novel
scientiﬁc approaches are being applied which show some promise,
especially in regard to pre-operative diagnosis of these tumours.
Studies evaluating chromosomal abnormalities in MPT have iden-
tiﬁed distinct chromosomal abnormalities associated with malig-
nancy,15,34 and immunohistochemical studies have shown
a correlation between c-Kit positivity and malignancy.1 Other
authors have postulated that novel imaging techniques such as
FDG-PET scanning represent signiﬁcant advances in diagnosis and
staging of these lesions.4,35 As pre-operative diagnosis improves,
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continue to improve, particularly for malignant phyllodes tumour.
2. Conclusions
Breast sarcoma is a rare condition. It may present in a similar
fashion to other primary breast malignancies, and yet is often
refractory to diagnosis by conventional triple assessment. Core
biopsy produces a signiﬁcant improvement in pre-operative diag-
nosis rates. Given the importance of making the diagnosis pre-
operatively we recommend core biopsy in all patients in whom the
possibility of sarcoma or MPT is considered. Excision biopsy should
not be undertaken unless repeated attempts at pre-operative diag-
nosis are unsuccessful. In this, as in other respects, breast sarcoma is
far more comparable to soft-tissue sarcoma at other sites than to
epithelial malignancy of the breast. The ﬁrst-line treatment is
surgical excision with adequate margins, with small survival
advantages shown for post-operative radiotherapy. Local lymph
node sampling or routine excision cannot currently be recom-
mended. Response rates to systemic therapies remain poor, rein-
forcing the need for accurate pre-operative diagnostic strategies and
appropriate surgical management. Future directions are, therefore,
likely to revolve around improving this area of patient care.
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